80
Participants
Start Date
February 6, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
May 31, 2027
Tibulizumab
Anti BAFF/IL-17 antibody
Placebo
Placebo (inactive)
RECRUITING
Institute of Rheumatology - PPDS, Belgrade
RECRUITING
IRIS Research and Development LLC, Plantation
RECRUITING
University of Michigan Hospital, Ann Arbor
RECRUITING
University of Iowa, Iowa City
RECRUITING
Rheumatology Associates, Arlington
RECRUITING
UCSD Altman Clinical and Translational Research Institute Center for Clinical Research, La Jolla
RECRUITING
STAT Research S.A., Buenos Aires
RECRUITING
Centro de Investigaciones Médicas Tucumán, San Miguel de Tucumán
RECRUITING
Organización Médica de Investigación, Buenos Aires
RECRUITING
Centro de Investigación y Prevención Cardiovascular-Arenales, Buenos Aires
RECRUITING
Instituto de Investigación Clínica TyT, Buenos Aires
RECRUITING
Centro Medico de Estudios Clinicos y Farmacovigilancia (CECYF), Buenos Aires
RECRUITING
Consultorios Médicos Dr. Doreski, Buenos Aires
RECRUITING
Aberdeen Royal Infirmary, Aberdeen
RECRUITING
Royal National Hospital for Rheumatic Diseases, Bath
RECRUITING
Ninewells Hospital, Dundee
RECRUITING
Aintree University Hospital, Liverpool
RECRUITING
Royal Free Hospital, London
RECRUITING
Haywood Community Hospital, Stoke-on-Trent
Zura Bio Inc
INDUSTRY